Yesterday, Oct. 19, 2015, 37 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $303.88 to $2,458,825.00.

Highlighted Stocks Traded by Insiders:

Neurocrine Biosciences (NBIX) - FREE Research Report

Gorman Kevin Charles, who is President and CEO at Neurocrine Biosciences, sold 33,500 shares at $47.77 on Oct. 19, 2015. Following this transaction, the President and CEO owned 217,452 shares meaning that the stake was reduced by 13.35% with the 33,500-share transaction.

OBrien Christopher Flint, who is Chief Medical Officer at Neurocrine Biosciences, sold 25,000 shares at $47.78 on Oct. 19, 2015. Following this transaction, the Chief Medical Officer owned 125,044 shares meaning that the stake was reduced by 16.66% with the 25,000-share transaction.

Coughlin Timothy P, who is Chief Financial Officer at Neurocrine Biosciences, sold 25,000 shares at $47.78 on Oct. 19, 2015. Following this transaction, the Chief Financial Officer owned 126,374 shares meaning that the stake was reduced by 16.52% with the 25,000-share transaction.

Bozigian Haig P., who is Chief Development Officer at Neurocrine Biosciences, sold 25,000 shares at $47.78 on Oct. 19, 2015. Following this transaction, the Chief Development Officer owned 106,829 shares meaning that the stake was reduced by 18.96% with the 25,000-share transaction.

Grigoriadis Dimitri E., who is Chief Research Officer at Neurocrine Biosciences, sold 25,000 shares at $47.77 on Oct. 19, 2015. Following this transaction, the Chief Research Officer owned 105,308 shares meaning that the stake was reduced by 19.19% with the 25,000-share transaction.

Gano Kyle, who is Chief Business Development Off at Neurocrine Biosciences, sold 25,000 shares at $47.77 on Oct. 19, 2015. Following this transaction, the Chief Business Development Off owned 51,613 shares meaning that the stake was reduced by 32.63% with the 25,000-share transaction.

The shares most recently traded at $48.79, up $1.02, or 2.09% since the insider transaction. Historical insider transactions for Neurocrine Biosciences go as follows:

  • 4-Week # shares sold: 15,000
  • 12-Week # shares sold: 15,000
  • 24-Week # shares sold: 15,000

The average volume for Neurocrine Biosciences has been 1.1 million shares per day over the past 30 days. Neurocrine Biosciences has a market cap of $4.1 billion and is part of the health care sector and drugs industry. Shares are up 119.25% year-to-date as of the close of trading on Monday.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. Currently, there are 8 analysts who rate Neurocrine Biosciences a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NBIX - FREE

TheStreet Quant Ratings

rates Neurocrine Biosciences as a

hold

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, poor profit margins and feeble growth in the company's earnings per share. Get the full

Neurocrine Biosciences Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Helen of Troy (HELE) - FREE Research Report

Grass Brian, who is Chief Financial Officer at Helen of Troy, sold 333 shares at $99.49 on Oct. 19, 2015. Following this transaction, the Chief Financial Officer owned 2,678 shares meaning that the stake was reduced by 11.06% with the 333-share transaction.

The shares most recently traded at $101.19, up $1.70, or 1.68% since the insider transaction. Historical insider transactions for Helen of Troy go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 5,000
  • 24-Week # shares sold: 5,000

The average volume for Helen of Troy has been 262,000 shares per day over the past 30 days. Helen of Troy has a market cap of $2.8 billion and is part of the consumer goods sector and consumer durables industry. Shares are up 55.26% year-to-date as of the close of trading on Monday.

Helen of Troy Limited, together with its subsidiaries, designs, develops, imports, markets, and distributes a portfolio of consumer products worldwide. It operates through four segments: Housewares, Healthcare/Home Environment, Nutritional Supplements, and Personal Care. The company has a P/E ratio of 20.6. Currently, there is 1 analyst who rates Helen of Troy a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on HELE - FREE

TheStreet Quant Ratings

rates Helen of Troy as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Helen of Troy Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Facebook (FB) - FREE Research Report

Fischer David B., who is VP Marketing & Bus. Part. at Facebook, sold 15,000 shares at $95.02 on Oct. 19, 2015. Following this transaction, the VP Marketing & Bus. Part. owned 230,262 shares meaning that the stake was reduced by 6.12% with the 15,000-share transaction.

The shares most recently traded at $99.17, up $4.15, or 4.18% since the insider transaction. Historical insider transactions for Facebook go as follows:

  • 4-Week # shares sold: 19,500
  • 12-Week # shares sold: 164,899
  • 24-Week # shares sold: 336,784

The average volume for Facebook has been 32.8 million shares per day over the past 30 days. Facebook has a market cap of $220.4 billion and is part of the technology sector and internet industry. Shares are up 26.21% year-to-date as of the close of trading on Monday.

Facebook, Inc. operates as a social networking company worldwide. It provides a set of development tools and application programming interfaces that enable developers to integrate with Facebook to create mobile and Web applications. The company has a P/E ratio of 99.5. Currently, there are 29 analysts who rate Facebook a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on FB - FREE

TheStreet Quant Ratings

rates Facebook as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Facebook Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.